Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma-Reference-Cited by-同舟云学术

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

Published:2017-06 Issue:6 Volume:28 Page:1250-1259
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kim H.R.,Kang H.N.,Shim H.S.,Kim E.Y.,Kim J.,Kim D.J.,Lee J.G.,Lee C.Y.,Hong M.H.,Kim S.-M.,Kim H.,Pyo K.-H.,Yun M.R.,Park H.J.,Han J.Y.,Youn H.A.,Ahn M.-J.,Paik S.,Kim T.-M.,Cho B.C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/6/1250/17646342/mdx098.pdf

Reference25 articles.

1. The evolution of therapies in non-small cell lung cancer;Boolell;Cancers (Basel),2015

2. Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis;Dubey;Chin J Cancer,2016

3. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer;Kim;JCO,2013

4. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps;Ilie;Cancer Med,2015

5. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer;Weiss;Sci Transl Med,2010

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery;Methods in Molecular Biology;2024

2. Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer;Journal of Clinical Investigation;2023-11-01

3. Application status and future prospects of the PDX model in lung cancer;Frontiers in Oncology;2023-03-24

4. Establishment and Characterization of Patient-Derived Xenograft Model of Non-Small-Cell Lung Cancer Derived from Malignant Pleural Effusions;Cancer Management and Research;2023-02

5. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression;Cancer Letters;2022-10